BioNexus Gene Lab Corp
BGLC Nasdaq Services-Medical Laboratories Financials FY2018–FY2025
Revenue
Total sales reported in the income statement.
$7.4M
21.9%
vs prior year
Operating margin
Operating income as a share of revenue.
−39.9%
23.4 pts
Net income
Profit after all expenses, interest and tax.
−$3.0M
Free cash flow
Cash from operations minus capital spending.
−$1.9M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
What BioNexus Gene Lab Corp does
No business description yet.
- Legal name
- BioNexus Gene Lab Corp
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 14, 2026
- Accession · CIK
- 0001477932-26-002218
0001737523
Revenue and margins
BioNexus Gene Lab Corp had $7.4M of revenue in fiscal 2025, down 21.9% on the year before.
FY18
Revenue $0.2M
FY19
Revenue $0.1M
FY20
Revenue $11.4M
FY21
Revenue $13.4M
FY22
Revenue $10.9M
FY23
Revenue $9.8M
FY24
Revenue $9.5M
FY25
Revenue $7.4M
Q3 '23
Revenue $2.6M
Q4 '23
Revenue $2.3M
Q1 '24
Revenue $2.4M
Q2 '24
Revenue $2.0M
Q3 '24
Revenue $2.6M
Q4 '24
Revenue $2.5M
Q1 '25
Revenue $2.1M
Q2 '25
Revenue $2.3M
Q3 '25
Revenue $2.5M
Q4 '25
Revenue $0.5M
Q1 '26
Revenue $0.0M
Q2 '26
Revenue $0.1M
FY18
Gross 13.6%
Operating 28.2%
Net 12.5%
FCF −110.5%
FY19
Gross 44.0%
Operating −217.1%
Net −194.1%
FCF −181.2%
FY20
Gross 15.1%
Operating 11.2%
Net 9.6%
FCF 1.2%
FY21
Gross 17.0%
Operating 7.9%
Net 5.6%
FCF 0.0%
FY22
Gross 11.5%
Operating −2.7%
Net −3.3%
FCF 5.0%
FY23
Gross 13.6%
Operating −26.5%
Net −26.9%
FCF −20.2%
FY24
Gross 13.6%
Operating −16.5%
Net −16.8%
FCF −24.4%
FY25
Gross 14.6%
Operating −39.9%
Net −40.2%
FCF −25.3%
Gross
Operating
Net
FCF
Q3 '23
Gross 13.9%
Operating −99.0%
Net −102.2%
FCF −40.5%
Q4 '23
Gross 11.7%
Operating 11.3%
Net 13.6%
FCF −34.5%
Q1 '24
Gross 15.3%
Operating −3.3%
Net −4.4%
FCF −2.5%
Q2 '24
Gross 14.6%
Operating 13.1%
Net 10.1%
FCF −34.1%
Q3 '24
Gross 12.4%
Operating −50.9%
Net −51.1%
FCF −68.5%
Q4 '24
Gross 12.3%
Operating −16.5%
Net −13.8%
FCF 8.5%
Q1 '25
Gross 16.1%
Operating −28.9%
Net −29.2%
FCF −39.0%
Q2 '25
Gross 16.3%
Operating −27.0%
Net −27.3%
FCF −33.6%
Q3 '25
Gross 14.8%
Operating −27.6%
Net −27.9%
FCF −48.9%
Q4 '25
Gross −0.8%
Operating −213.5%
Net −214.2%
FCF 198.4%
Q1 '26
Gross −3.5%
Operating −2,370.6%
Net −2,384.2%
FCF −649.1%
Q2 '26
Gross 17.1%
Operating −370.6%
Net −376.0%
FCF −554.9%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY18
Net income $0.0M
FY19
Net income −$0.2M
FY20
Net income $1.1M
FY21
Net income $0.8M
FY22
Net income −$0.4M
FY23
Net income −$2.6M
FY24
Net income −$1.6M
FY25
Net income −$3.0M
Q3 '23
Net income −$2.6M
Q4 '23
Net income $0.3M
Q1 '24
Net income −$0.1M
Q2 '24
Net income $0.2M
Q3 '24
Net income −$1.3M
Q4 '24
Net income −$0.3M
Q1 '25
Net income −$0.6M
Q2 '25
Net income −$0.6M
Q3 '25
Net income −$0.7M
Q4 '25
Net income −$1.0M
Q1 '26
Net income −$0.5M
Q2 '26
Net income −$0.3M
FY18
Diluted EPS $0.00
FY19
Diluted EPS $0.00
FY20
Diluted EPS $0.01
FY21
Diluted EPS —
FY22
Diluted EPS —
FY23
Diluted EPS −$0.17
FY24
Diluted EPS −$0.09
FY25
Diluted EPS —
Q3 '23
Diluted EPS —
Q4 '23
Diluted EPS —
Q1 '24
Diluted EPS −$0.01
Q2 '24
Diluted EPS $0.11
Q3 '24
Diluted EPS −$0.75
Q4 '24
Diluted EPS $0.55
Q1 '25
Diluted EPS −$0.35
Q2 '25
Diluted EPS −$0.34
Q3 '25
Diluted EPS −$0.40
Q4 '25
Diluted EPS —
Q1 '26
Diluted EPS −$0.23
Q2 '26
Diluted EPS −$0.12
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY18
Return on capital —
Return on equity 1.7%
Return on assets 1.6%
FY19
Return on capital —
Return on equity −18.6%
Return on assets −17.1%
FY20
Return on capital —
Return on equity 28.1%
Return on assets 19.3%
FY21
Return on capital —
Return on equity 10.9%
Return on assets 7.6%
FY22
Return on capital —
Return on equity −5.1%
Return on assets −3.9%
FY23
Return on capital —
Return on equity −32.2%
Return on assets −26.1%
FY24
Return on capital —
Return on equity −17.8%
Return on assets −14.6%
FY25
Return on capital —
Return on equity −35.2%
Return on assets −30.3%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was −$1.9M in fiscal 2025, −25.3% of revenue. Cash from operations minus capital spending.
FY18
Free cash flow −$0.2M
FY19
Free cash flow −$0.2M
FY20
Free cash flow $0.1M
FY21
Free cash flow $0.0M
FY22
Free cash flow $0.6M
FY23
Free cash flow −$2.0M
FY24
Free cash flow −$2.3M
FY25
Free cash flow −$1.9M
Q3 '23
Free cash flow −$1.0M
Q4 '23
Free cash flow −$0.8M
Q1 '24
Free cash flow −$0.1M
Q2 '24
Free cash flow −$0.7M
Q3 '24
Free cash flow −$1.8M
Q4 '24
Free cash flow $0.2M
Q1 '25
Free cash flow −$0.8M
Q2 '25
Free cash flow −$0.8M
Q3 '25
Free cash flow −$1.2M
Q4 '25
Free cash flow $1.0M
Q1 '26
Free cash flow −$0.1M
Q2 '26
Free cash flow −$0.4M
FY18
Cash from operations −$0.3M
Capital spending −$0.0M
FY19
Cash from operations −$0.2M
Capital spending $0.0M
FY20
Cash from operations $0.6M
Capital spending $0.4M
FY21
Cash from operations $0.0M
Capital spending $0.0M
FY22
Cash from operations $0.6M
Capital spending $0.0M
FY23
Cash from operations −$1.8M
Capital spending $0.1M
FY24
Cash from operations −$2.1M
Capital spending $0.2M
FY25
Cash from operations −$1.8M
Capital spending $0.0M
Cash from operations
Capital spending
Q3 '23
Cash from operations −$0.9M
Capital spending $0.1M
Q4 '23
Cash from operations −$0.8M
Capital spending $0.0M
Q1 '24
Cash from operations −$0.0M
Capital spending $0.0M
Q2 '24
Cash from operations −$0.7M
Capital spending $0.0M
Q3 '24
Cash from operations −$1.6M
Capital spending $0.2M
Q4 '24
Cash from operations $0.2M
Capital spending $0.0M
Q1 '25
Cash from operations −$0.8M
Capital spending $0.0M
Q2 '25
Cash from operations −$0.7M
Capital spending $0.0M
Q3 '25
Cash from operations −$1.2M
Capital spending $0.0M
Q4 '25
Cash from operations $1.0M
Capital spending $0.0M
Q1 '26
Cash from operations −$0.1M
Capital spending $0.0M
Q2 '26
Cash from operations −$0.4M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
BioNexus Gene Lab Corp returned — to shareholders in fiscal 2025. The diluted share count rose 0.0%.
FY18
Dividends —
Buybacks —
FY19
Dividends —
Buybacks —
FY20
Dividends —
Buybacks —
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
Dividends
Buybacks
FY18
Diluted shares 0.07B
FY19
Diluted shares 0.09B
FY20
Diluted shares 0.10B
FY21
Diluted shares —
FY22
Diluted shares —
FY23
Diluted shares 0.02B
FY24
Diluted shares 0.02B
FY25
Diluted shares —
Balance sheet
Cash, debt and the ratios that show how comfortably BioNexus Gene Lab Corp can carry it.
FY18
Cash $1.3M
Debt —
FY19
Cash $0.9M
Debt —
FY20
Cash $2.8M
Debt —
FY21
Cash $2.1M
Debt —
FY22
Cash $2.1M
Debt —
FY23
Cash $4.5M
Debt —
FY24
Cash $2.9M
Debt —
FY25
Cash $2.4M
Debt —
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.1M | $2.1M | $4.5M | $2.9M | $2.4M |
| Interest coverage | — | −23.3x | −186.6x | — | — |
| Current ratio | 3.1x | 3.0x | 4.9x | 3.8x | 10.5x |
| Quick ratio | 2.4x | 2.5x | 4.2x | 3.1x | 9.2x |
| Total assets | $9.6M | $8.7M | $11.4M | $10.4M | $9.3M |
| Total liabilities | $2.4M | $2.1M | $1.7M | $2.1M | $0.6M |
| Shareholders' equity | $7.2M | $6.7M | $9.7M | $8.3M | $8.6M |
| Net debt (− = net cash) | — | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | ✓ | ✕ | ✓ | ✓ | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✓ | ✓ | ✓ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✕ | ✓ | ✕ | ✕ | ✕ | ✓ | ✕ |
| Cash from operations exceeds net income | ✕ | ✓ | ✕ | ✕ | ✓ | ✓ | ✕ | ✓ |
| Debt fell relative to assets | — | — | — | — | — | — | — | — |
| Current ratio rose | — | ✕ | ✕ | ✓ | ✕ | ✓ | ✕ | ✓ |
| Share count didn't rise | — | ✕ | ✕ | — | — | — | ✕ | — |
| Gross margin rose | — | ✓ | ✕ | ✓ | ✕ | ✓ | ✕ | ✓ |
| Revenue rose relative to assets | — | ✕ | ✓ | ✓ | ✕ | ✕ | ✓ | ✕ |
| F-score | — / 3 | 2 / 8 | 4 / 8 | 5 / 7 | 2 / 7 | 3 / 7 | 2 / 8 | 3 / 7 |
| Accruals ratio | 18.2% | −2.0% | 9.5% | 7.5% | −9.9% | −8.0% | 4.5% | −11.6% |
| Altman Z'' | 17.24 | 12.86 | 6.11 | 7.71 | 6.60 | 7.46 | 5.50 | 13.26 |
8 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0.2M | $0.1M | $11.4M | $13.4M | $10.9M | $9.8M | $9.5M | $7.4M |
| Net interest income | — | — | — | — | $0.0M | $0.0M | — | — |
| Gross profit | $0.0M | $0.1M | $1.7M | $2.3M | $1.3M | $1.3M | $1.3M | $1.1M |
| Research and development | — | — | — | — | — | $0.1M | $0.0M | $0.1M |
| Operating income | $0.1M | −$0.3M | $1.3M | $1.1M | −$0.3M | −$2.6M | −$1.6M | −$3.0M |
| Interest expense | — | — | — | — | $0.0M | $0.0M | — | — |
| Pretax income | — | −$0.3M | $1.3M | $1.0M | −$0.3M | −$2.6M | −$1.6M | −$3.0M |
| Income tax | −$0.0M | $0.0M | — | −$0.3M | −$0.1M | −$0.0M | −$0.0M | $0.0M |
| Net income | $0.0M | −$0.2M | $1.1M | $0.8M | −$0.4M | −$2.6M | −$1.6M | −$3.0M |
| Net income to common | — | −$0.2M | — | — | — | −$2.6M | −$1.6M | −$3.0M |
| Diluted EPS | $0.00 | $0.00 | $0.01 | — | — | −$0.17 | −$0.09 | — |
| Diluted shares | 0.07B | 0.09B | 0.10B | — | — | 0.02B | 0.02B | — |
| Cash flow | ||||||||
| Cash from operations | −$0.3M | −$0.2M | $0.6M | $0.0M | $0.6M | −$1.8M | −$2.1M | −$1.8M |
| Capital expenditure | −$0.0M | $0.0M | $0.4M | $0.0M | $0.0M | $0.1M | $0.2M | $0.0M |
| Free cash flow | −$0.2M | −$0.2M | $0.1M | $0.0M | $0.6M | −$2.0M | −$2.3M | −$1.9M |
| Depreciation and amortization | $0.0M | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M |
| Stock-based compensation | — | — | — | — | — | — | $0.1M | $0.8M |
| Balance sheet | ||||||||
| Cash and short-term investments | $1.3M | $0.9M | $2.8M | $2.1M | $2.1M | $4.5M | $2.9M | $2.4M |
| Finance lease liabilities | $0.1M | $0.1M | $0.1M | $0.0M | — | — | — | $0.0M |
| Current assets | $1.3M | $0.9M | $8.0M | $7.1M | $6.0M | $8.0M | $7.4M | $5.4M |
| Current liabilities | $0.1M | $0.1M | $3.4M | $2.3M | $2.0M | $1.6M | $2.0M | $0.5M |
| Inventory | $0.0M | $0.0M | $1.2M | $1.5M | $1.0M | $1.1M | $1.4M | $0.7M |
| Property and equipment, net | $0.3M | $0.3M | $1.8M | $1.6M | $1.5M | $1.5M | $1.5M | $1.6M |
| Total assets | $1.7M | $1.2M | $10.1M | $9.6M | $8.7M | $11.4M | $10.4M | $9.3M |
| Total liabilities | $0.1M | $0.1M | $3.5M | $2.4M | $2.1M | $1.7M | $2.1M | $0.6M |
| Shareholders' equity | $1.5M | $1.1M | $6.7M | $7.2M | $6.7M | $9.7M | $8.3M | $8.6M |
| Margins | ||||||||
| Gross margin | 13.6% | 44.0% | 15.1% | 17.0% | 11.5% | 13.6% | 13.6% | 14.6% |
| Operating margin | 28.2% | −217.1% | 11.2% | 7.9% | −2.7% | −26.5% | −16.5% | −39.9% |
| EBITDA margin | 47.3% | −184.3% | 12.0% | 8.6% | −1.8% | −25.7% | −15.5% | −38.4% |
| Net margin | 12.5% | −194.1% | 9.6% | 5.6% | −3.3% | −26.9% | −16.8% | −40.2% |
| FCF margin | −110.5% | −181.2% | 1.2% | 0.0% | 5.0% | −20.2% | −24.4% | −25.3% |
| Net interest share of revenue | — | — | — | — | 0.1% | 0.1% | — | — |
| Returns | ||||||||
| Return on capital employed | 3.8% | −23.4% | 18.9% | 14.6% | −4.3% | −26.5% | −18.6% | −34.0% |
| Return on equity | 1.7% | −18.6% | 28.1% | 10.9% | −5.1% | −32.2% | −17.8% | −35.2% |
| Return on assets | 1.6% | −17.1% | 19.3% | 7.6% | −3.9% | −26.1% | −14.6% | −30.3% |
| Return on tangible equity | 1.7% | −22.0% | 16.4% | 10.5% | −5.3% | −27.2% | −19.2% | −34.6% |
| Growth | ||||||||
| Revenue growth | — | −40.2% | 8,868.8% | 17.3% | −18.2% | −10.6% | −2.7% | −21.9% |
| Net income growth | — | −1,030.2% | — | −31.3% | −147.4% | — | — | — |
| FCF growth | — | — | — | −95.4% | 9,096.7% | −457.3% | — | — |
| Share count change | — | 30.2% | 19.2% | — | — | — | 12.2% | — |
| Financial health | ||||||||
| Interest coverage | — | — | — | — | −23.3x | −186.6x | — | — |
| Current ratio | 20.6x | 17.1x | 2.4x | 3.1x | 3.0x | 4.9x | 3.8x | 10.5x |
| Quick ratio | 20.4x | 17.0x | 2.0x | 2.4x | 2.5x | 4.2x | 3.1x | 9.2x |
| Capital allocation | ||||||||
| Capex / revenue | −18.7% | 10.1% | 3.7% | 0.0% | 0.0% | 1.5% | 2.4% | 0.5% |
| Stock comp / revenue | — | — | — | — | — | — | 1.5% | 10.7% |
| Quality scores | ||||||||
| Piotroski F-score | — | 2.0 | 4.0 | 5.0 | 2.0 | 3.0 | 2.0 | 3.0 |
| Altman Z'' | 17.2 | 12.9 | 6.1 | 7.7 | 6.6 | 7.5 | 5.5 | 13.3 |
| Accruals ratio | 18.2% | −2.0% | 9.5% | 7.5% | −9.9% | −8.0% | 4.5% | −11.6% |
Source: SEC EDGAR XBRL filings (CIK 0001737523). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.